Clinical Trials
14 trialsNCT07467772 2026-05-22
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07089992 2026-05-14
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02834013 2026-05-13
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02180867 2026-05-04
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT03967834 2026-02-10
MIRAS
Institut Claudius Regaud
Phase NA Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT02494570 2023-04-07
AMPECT
Aadi Bioscience, Inc.
Phase 2 Completed
NCT05625919 2022-11-28
A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT05617105 2022-11-15
PEComesCells
University Hospital, Strasbourg, France
Unknown
NCT03817515 2022-03-16
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
Aadi Bioscience, Inc.
Approved for marketing
NCT03916575 2019-05-01
PEComas
University Hospital, Strasbourg, France
Unknown
NCT02334930 2016-08-22
PEC-Hem
University Hospital, Bordeaux
Completed
NCT01690871 2013-08-02
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Novartis
Phase 2 Withdrawn